Advanced Malignancies Clinical Trials

A listing of Advanced Malignancies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 855 clinical trials
Featured trial
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.  

  • 0 views
  • 04 Aug, 2020
  • 3 locations
Featured trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

malignant solid tumor
solid tumors
advanced solid tumor
solid tumor
  • 448 views
  • 24 Nov, 2021
  • 8 locations
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

primary tumor
solid tumors
metastasis
administration intravenous
primary cancer
  • 56 views
  • 25 Aug, 2021
  • 57 locations
Featured trial
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.  

pd-l1
cancer
measurable disease
metastatic cancer
  • 100 views
  • 10 Dec, 2020
  • 23 locations
Featured trial
Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG. Clinical trial NCT02449239, VB4-845-02-IIIA.

Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG. Clinical trial NCT02449239, VB4-845-02-IIIA.

serum bilirubin
neutrophil count
cancer
  • 177 views
  • 02 Sep, 2021
  • 1 location
Featured trial
ATR Inhibitor BAY 1895344 plus pembrolizumab in advanced solid tumors (GI, Pancreatic, mCRPC, NSCLC)

pembrolizumab, may improve antitumor responses in advanced cancer patients with DDR aberrations, at an acceptable safety profile and an expected positive benefit/risk ratio.

EGFR
pembrolizumab
measurable disease
  • 12 views
  • 13 Oct, 2021
  • 11 locations
Featured trial
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.  This investigational intervention

metastatic cervical cancer
urothelial carcinoma
carcinoma
ovarian cancer
  • 156 views
  • 23 Nov, 2020
  • 4 locations
Featured trial
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention

advanced cancer
cancer
  • 134 views
  • 14 Dec, 2020
  • 4 locations
Featured trial
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.

malignant solid tumor
solid tumors
advanced solid tumor
solid tumor
  • 114 views
  • 19 Feb, 2021
  • 10 locations
Featured trial
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

  • 317 views
  • 25 Mar, 2021
  • 4 locations